Research opportunities in transfusion medicine

JAMA

Volumn 285, Issue 5, 2001, Pages 577-580

  Silberstein, Leslie E ^a,c   Toy, Pearl ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD STORAGE; BLOOD TRANSFUSION; CELL ISOLATION; CELL POPULATION; CELL TRANSPLANTATION; DENDRITIC CELL; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE;

EID: 0035819479     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.5.577     Document Type: Article

References (29)

1. Collection and transfusion of blood and blood components in the United States
2. Risks of transfusion transmitted infection
3. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients
4. Functional aspects of red cell antigens
5. DNA from blood samples can be used to genotype patients who have recently received a transfusion
6. Suspension arrays for high throughput, multiplexed single nucleotide polymorphism gentoyping
7. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
8. Transfusion practice for patients with sickle cell disease
9. Platelet transfusion
10. Graft-versus-leukemia reactions after bone marrow transplantation
11. Transfusion-associated immunomodulation and universal white cell reduction
12. Universal WBC reduction
13. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a psoralen and long-wavelength ultraviolet light
14. The prospects for red-cell substitutes
15. The biology of hematopoietic stem cells
16. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4
17. Gene-modified dendritic cells for use in tumor vaccines
18. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
19. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
20. New strategies for preventing graft-versus-host disease
21. + T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody
22. Transplantation of anergic histoincompatible bone marrow allografts
23. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo
24. Deaths tied to mad cow disease on the rise
25. The new generation of blood components
26. Achieving alloengraftment without graft-versus-host disease
27. Prospects for adoptive T cell therapy
28. Hepatocytes from non-hepatic adult stem cells